Skip Nav Destination
Letter|
April 18, 2024
Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US
Christina Waldron
Christina Waldron
Yale University School of Medicine, New Haven, Connecticut, United States
https://orcid.org/0000-0003-0286-6599
Search for other works by this author on:
Daniel Wang
Daniel Wang
Yale University School of Medicine, New Haven, Connecticut, United States
Search for other works by this author on:
Cecily Allen
Cecily Allen
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Search for other works by this author on:
Robert D Bona
Robert D Bona
Yale University, New Haven, Connecticut, United States
Search for other works by this author on:
Adam Cuker
Adam Cuker
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Search for other works by this author on:
George Goshua
Yale University School of Medicine, New Haven, Connecticut, United States
Search for other works by this author on:
Blood blood.2024024209.
Article history
Submitted:
February 8, 2024
Revision Received:
April 8, 2024
Accepted:
April 10, 2024
Don't already have an account? Create Account
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal